Stockscreener 앱 받기
6.08
2.25%
-0.14
Verastem Inc 주식(VSTM)의 최신 뉴스
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Verastem price target raised to $9 from $7 at B. Riley - MSN
Vanguard Group Inc. Increases Stake in Verastem Inc. - GuruFocus.com
B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating -January 31, 2025 at 09:19 am EST - Marketscreener.com
Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL
Verastem's Next Big Move: Key Revelations Expected at Major Biotech Conference - StockTitan
Verastem's (VSTM) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Mizuho maintains Verastem stock outperform with $9 target By Investing.com - Investing.com Australia
Mizuho maintains Verastem stock outperform with $9 target - MSN
Cantor Fitzgerald Estimates Verastem FY2025 Earnings - Defense World
Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL
Cantor Fitzgerald Forecasts Verastem FY2025 Earnings - MarketBeat
Verstem avutometinib and defactinib combo gains FDA priority review - Seeking Alpha
Verastem Expands Oncology Pipeline with VS-7375 Acquisition - TipRanks
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
Barclays PLC Acquires 47,094 Shares of Verastem, Inc. (NASDAQ:VSTM) - MarketBeat
Verastem Oncology Secures FDA Priority Review for Groundbreaking Cancer Drug Combination - StockTitan
KRAS Inhibitors Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines - Barchart
Verastem appoints new COO with extensive biotech experience By Investing.com - Investing.com South Africa
Verastem appoints new COO with extensive biotech experience - Investing.com India
Verastem Appoints Matthew E. Ros as COO - TipRanks
Verastem Secures $150 Million Note Purchase Agreement with Oberland Capital - Defense World
Verastem stock retains Buy rating as KRASG12D program and LGSOC launch gain traction - Investing.com Canada
Verastem, Inc. (NASDAQ:VSTM) Shares Sold by Jane Street Group LLC - Defense World
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - BioSpace
Verastem Oncology Names Pharma Veteran Matthew Ros as COO Ahead of Key Cancer Drug Launch - StockTitan
Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer - Marketscreener.com
Dan Paterson Sells 8,568 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock - MarketBeat
Verastem CEO sells shares worth $44,896 By Investing.com - Investing.com Australia
Verastem CEO sells shares worth $44,896 - Investing.com India
Verastem licenses GenFleet's KRAS inhibitor - The Pharma Letter
Verastem Oncology: $150 Million Credit Facility Deal Signed - Pulse 2.0
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
Verastem Oncology announces debt refinancing with Oberland Capital - MSN
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - BioSpace
Royal Bank of Canada Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World
FDA reviewing oral combination treatment for ovarian cancer - Myeloma Research News
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Follicular Lymphoma Market Expected to rise, 2034 | - openPR
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem's SWOT analysis: biotech firm's stock rides on avutometinib approval - Investing.com India
Barclays PLC Has $167,000 Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Geode Capital Management LLC Raises Stock Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
3.95%
2.39%
자본화:
|
볼륨(24시간):